Kwon Sun-Hong, Park Ji Kyoung, Baek Hee Jo, Nam Jin Hyun, Min Serim, Cho Ae-Ryeo, Jung Aeran, Park Young-Shil
School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.
Department of Pediatrics, Inje University College of Medicine, Busan Paik Hospital, Busan, Republic of Korea.
Haemophilia. 2025 Jul;31(4):687-695. doi: 10.1111/hae.70064. Epub 2025 May 30.
Overall use of factor VIII (FVIII) and prophylactic use have increased in South Korea over the past decade. However, there are no nationwide outcome data demonstrating its impact. This study aimed to identify patients with haemophilia A (PwHA) and observe trends in joint-related outcomes and life-threatening haemorrhages using national claims data.
This serial cross-sectional study analysed claims data from the Health Insurance and Review Assessment in South Korea. PwHA treated with FVIII at least twice between 2007 and 2022 were identified. We observed joint procedures, life-threatening haemorrhages and comorbidities between 2008 and 2021.
The number of identified PwHAs was 1193 in 2008 and 1517 in 2021. The proportion of older adult patients has increased over the past 14 years. The joint procedure rates per 1000 patients were 61.2 (95% CI 48.0‒76.9) in 2008 and 17.1 (11.2‒25.1) in 2021. The rate was highest in patients with a severe phenotype. Annually, less than 2% of patients experienced life-threatening haemorrhages, with approximately 90% of the cases attributed to central nervous system and gastrointestinal bleeding. The prevalence of hypertension and diabetes increased over the years (6% in 2008 and 15% in 2021, and 6% in 2008 and 9% in 2021, respectively).
This study revealed previously unreported long-term trends in haemophilia-related outcomes and comorbidities in Korean PwHA. Although the number of older adult patients has increased, joint-related complications have decreased over time. The trends, observed over 14 years, provide valuable insights for enhancing the treatment of PwHA.
在过去十年中，韩国的凝血因子VIII（FVIII）总体使用量和预防性使用量均有所增加。然而，尚无全国性的结果数据证明其影响。本研究旨在通过全国性索赔数据识别甲型血友病患者（PwHA），并观察关节相关结局和危及生命的出血情况的趋势。
这项系列横断面研究分析了韩国健康保险审查评估机构的索赔数据。确定了2007年至2022年间至少接受过两次FVIII治疗的PwHA。我们观察了2008年至2021年间的关节手术、危及生命的出血情况和合并症。
2008年确定的PwHA数量为1193例，2021年为1517例。在过去14年中，老年患者的比例有所增加。每1000例患者的关节手术率在2008年为61.2（95%CI 48.0‒76.9），2021年为17.1（11.2‒25.1）。该比率在重型表型患者中最高。每年，不到2%的患者发生危及生命的出血，其中约90%的病例归因于中枢神经系统和胃肠道出血。高血压和糖尿病的患病率多年来有所增加（分别从2008年的6%和2021年的15%，以及2008年的6%和2021年的9%）。
本研究揭示了韩国PwHA中此前未报告的血友病相关结局和合并症的长期趋势。尽管老年患者数量有所增加，但随着时间的推移，关节相关并发症有所减少。在14年中观察到的这些趋势为加强PwHA的治疗提供了有价值的见解。
